Pheochromocytoma/paraganglioma type 5 syndrome as a cause of secondary hypertension in a Colombian patient: case report

Juan Morales , Daniela Arturo , Miguel Folleco, .

Keywords: pheochromocytoma, paraganglioma, succinate dehydrogenase, hypertension, neuroendocrine tumors, multimodal imaging, precision medicine

Abstract

Pheochromocytoma is a tumor derived from neural crest cells able to produce sympathomimetic substances and, hence, a particular clinical picture. It is responsible
for less than 1% of high blood pressure cases, with an estimated incidence between 0.4 and 0.6 cases per 100,000 people each year, and an average survival of seven years. Pheochromocytoma is a solid tumor with a high genetic component, as heritability can reach 40%. Once diagnosed, its treatment and prognosis are partly conditioned by the associated pathogenic variants that can be documented, especially those related to RET, SDHx, VHL, and NF1 genes.
We present the case of a young woman with abdominal pain and high blood pressure, who was found to have a pheochromocytoma. Genetic testing detected a rare and recently discovered pathogenic variant: the SDHA:c.1A>C (p.Met1Leu). The patient responded adequately to the surgical treatment and continued the follow-up without documented recurrences.
The diagnostic approach for pheochromocytoma patients must start with a clinical suspicion, followed by metabolite measurement in blood and urine, and finally, imaging. Currently, technology development allows precision medicine applicability. In this case of pheochromocytoma, recent developments in precision medicine resulted in the detection of associated genetic components involving the patient and her family. Adequate screening of the index patient is required for documenting pathogenic variants and better characterizing the disease.

Downloads

Download data is not yet available.

References

Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108-19. https://doi.org/10.1038/nrc3648

Berends AM, Buitenwerf E, de Krijger RR, Veeger NJ, van der Horst-Schrivers AN, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018;51:68-73. https://doi.org/10.1016/j.ejim.2018.01.015

Neumann HP, Young Jr WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381:552-65. https://doi.org/10.1056/NEJMra1806651

Navarro EP, Osejo MC, Casas LA, Arango LG, Guzmán G. Experiencia en el manejo de feocromocitoma en los últimos 10 años: serie de casos. Rev Colomb Endocrinol Diabet Metab. 2016;3:33-6. https://doi.org/10.53853/encr.3.3.39

Fränkel F. A case of bilateral, completely latent adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis. CA Cancer J Clin. 1984;34:93-106. https://doi.org/10.3322/canjclin.34.2.93

Liu Z, Ma J, Jiménez C, Zhang M. Pheochromocytoma: A clinicopathologic and molecular study of 390 cases from a single center. Am J Surg Pathol. 2021;45:1155-65. https://doi.org/10.1097/PAS.0000000000001768

Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3:1204-12. https://doi.org/10.1001/jamaoncol.2017.0223

Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, et al. Current management of pheochromocytoma/paraganglioma: A guide for the practicing clinician in the era of precision medicine. Cancers. 2019;11:1505. https://doi.org/10.3390/cancers11101505

Lenders JW, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-42. https://doi.org/10.1210/jc.2014-1498

Jha A, De Luna K, Balili CA, Millo C, Paraiso CA, Ling A, et al. Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol. 2019;9:53. https://doi.org/10.3389/fonc.2019.00053

Burnichon N, Brière J-J, Libé R, Vescovo L, Riviere J, Tissier F, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011-20. https://doi.org/10.1093/hmg/ddq206

Molina L, Salgado J, Amado S. Feocromocitoma y paraganglioma: un reto más allá de la clínica. Rev Colomb Cancerol. 2021;25:3-12. https://doi.org/10.35509/01239015.586

Vasconcelos-Prado OD, López-García AE, García-Montalvo IA. Aspectos genéticos de los feocromocitomas y paragangliomas. J Negat No Posit Results. 2021;6:636-50. https://doi.org/10.19230/jonnpr.4020

Rueda-Galvis MV, Román-Gonzaléz A, Agredo-Delgado V. Síndrome de feocromocitomaparaganglioma tipo 5 asociado a mutación en el complejo de la succinato deshidrogenasa tipo A (SDHA), a propósito de un caso. Iatreia. 2023;36. https://doi.org/10.17533/udea.iatreia.187

Welander J, Garvin S, Bohnmark R, Isaksson L, Wiseman RW, Söderkvist P, et al. Germline SDHA mutation detected by next-generation sequencing in a young index patient with large paraganglioma. J Clin Endocrinol Metab. 2013;98:e1379-80. https://doi.org/10.1210/jc.2013-1963

van Der Tuin K, Mensenkamp AR, Tops CM, Corssmit EP, Dinjens WN, van de Horst-Schrivers AN, et al. Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: A nationwide study. J Clin Endocrinol Metab. 2018;103:438-45. https://doi.org/10.1210/jc.2017-01762

Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJ, Baudin E, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17:435-44. https://doi.org/10.1038/s41574-021-00492-3

Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112-37. https://doi.org/10.1007/s00259-019-04398-1

How to Cite
1.
Morales J, Arturo D, Folleco M. Pheochromocytoma/paraganglioma type 5 syndrome as a cause of secondary hypertension in a Colombian patient: case report. Biomed. [Internet]. 2024 May 31 [cited 2025 Apr. 4];44(Sp. 1):18-26. Available from: https://revistabiomedicaorg.biteca.online/index.php/biomedica/article/view/7152

Some similar items:

Published
2024-05-31

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code